Natural menstrual cycle and/or oral contraception diversely affect women metabolites. Longitudinal metabolic profiling under constant experimental conditions is thereby realistic to understand such effects. Thus, we investigated volatile organic compounds (VOCs) exhalation throughout menstrual cycles in 24 young and healthy women with-and without oral contraception. Exhaled VOCs were identified and quantified in trace concentrations via high-resolution real-time mass-spectrometry, starting from a menstruation and then repeated follow-up with six intervals including the next bleeding. Repeated measurements within biologically comparable groups were employed under optimized measurement setup. We observed pronounced and substance specific changes in exhaled VOC concentrations throughout all cycles with low intra-individual variations. Certain blood-borne volatiles changed significantly during follicular and luteal phases. Most prominent changes in endogenous VOCs were observed at the ovulation phase with respect to initial menstruation. Here, the absolute median abundances of alveolar ammonia, acetone, isoprene and dimethyl sulphide changed significantly (P-value ≤ 0.005) by 18.22↓, 13.41↓, 18.02↑ and 9.40↓%, respectively. These VOCs behaved in contrast under the presence of combined oral contraception; e.g. isoprene decreased significantly by 30.25↓%. All changes returned to initial range once the second bleeding phase was repeated. Changes in exogenous benzene, isopropanol, limonene etc. and smoking related furan, acetonitrile and orally originated hydrogen sulphide were rather nonspecific and mainly exposure dependent. Our observations could apprehend a number of known/pre-investigated metabolic effects induced by monthly endocrine regulations. Potential in vivo origins (e.g. metabolic processes) of VOCs are crucial to realize such effects. Despite ubiquitous confounders, we demonstrated the true strength of volatolomics for metabolic monitoring of menstrual cycle and contraceptives. These outcomes may warrant further studies in this direction to enhance our fundamental and clinical understanding on menstrual metabolomics and endocrinology. Counter-effects of contraception can be deployed for future noninvasive assessment of birth control pills. Our findings could be translated toward metabolomics of pregnancy, menopause and post-menopausal complications via breath analysis.
ScIenTIfIc RePoRTS | (2018) 8:10838 | DOI:10.1038/s41598-018-29221-z VOCs are either produced endogenously or absorbed and stored from habits and/or environment 17 . Thus, breath volatiles inherit potential for noninvasive assessment of physiology 18, 19 , pathophysiology [20] [21] [22] and therapy [23] [24] [25] . Thousands of volatile metabolites have already been quantified in trace concentrations (~ppbV-pptV range) in our exhalation. Human physiology plays the crucial role in bronco-pulmonary gas-exchange and thereby, on VOC exhalation 26, 27 . Thus, real-time profiling of exhaled alveolar VOC concentrations can contribute new insight into biochemical-and metabolic changes 28, 29 induced by normal or abnormal physiological effects. Real-time mass-spectrometric (MS) techniques e.g. proton transfer reaction (PTR)-Time of flight (ToF)-MS 30, 31 along with end-tidal/alveolar sampling 32, 33 have enabled online monitoring of immediate physiological changes within split-seconds [34] [35] [36] . These studies showed that concentration changes may be more important than the presence of unique breath VOC biomarkers.
In this perspective, effects of metabolic changes during normal menstrual cycle or effects induced by oral contraceptive pills are the prime concern of this study. Here, we follow-up changes in exhaled VOC concentrations from young and healthy women during their normal menstrual cycles and also throughout the cycles undergoing combined oral contraception by applying high-resolution PTR-ToF-MS. The following questions are addressed herein:
• What are the effects of natural menstrual cycle onto exhaled breath VOC concentrations in young and healthy women? • Do those effects differ under combined oral contraceptive medication?
• Are these changes related to known/pre-investigated metabolic effects induced by endocrine regulations throughout the cycle with-or without contraception? • Does the ovulation phase effect VOC concentrations in women without contraception?
Results
We observed pronounced differences in VOC concentrations throughout the menstrual cycle. These changes followed the female sex hormone regulation. Different behaviors were clearly noticeable between both groups of women. In both cohorts, these changes were VOC specific. Observed changes in endogenous and blood-borne VOCs were assignable to the ovulation phase in the cohort without contraception (from here on referred to as "control cohort"). Most VOC concentrations returned to initial levels once the reference phase (menstrual bleeding) was repeated in both cohorts. Figure 1 represents a semi-quantative expression of relative changes for selected breath VOC markers over the course of the entire study within the two cohorts of women (with-and without oral contraceptives). Normalized median values from each participant over 60 s of breathing are displayed. The 13 VOCs included in the heat-map were selected as they had significantly higher concentration in expiration than in inspiratory air. Inspiratory concentrations did not change during the measurements.
Changes in absolute abundances of VOCs during different phases of the menstrual cycle. Every indicated changes refer to the initial menstrual bleeding phase (MB). In the following section, only the most important and significant (i.e. P-value ≤ 0.005) changes are presented with a numeric value (in %) and all other cases are listed in Table 1 or Supplementary Table S1 .
• Changes on the day after the bleeding stopped:
Overall Exhaled abundances of hydrogen sulphide (H 2 S), toluene (C 7 H 8 ) and methyl-propyl sulphide (C 4 H 10 S) did not change significantly in any case. Surprisingly, no isoprene was exhaled by two women (P-16 and P-21) from the contraception cohort. Furan (C 4 H 4 O) was exhaled only by six smoking women from the control cohort. Although its exhalation closely mirrored isoprene no statistical relevance could be drawn due to low observation numbers. Detailed data on every observed change of different VOC concentrations and statistical significances (along with corresponding P-values) are listed in Table 1 and Supplementary Table S1 . . VOC data were normalized (for each participant) onto corresponding abundances in the third breath of the second minute from the initial menstrual bleeding phase (see method section). Red, green and blue colors represent relatively high, medium and low concentrations, respectively. The upper heat-map represents the data from the contraception cohort (P-13-P-24) and the lower heatmap represents the data from the control group (P-1-P-12). Isoprene was not exhaled by P-16 and P-21 (contraception cohort) and was thus assigned to '0' values in all measurement points. Qualitative regulations of two main female sex hormones are placed at the top (of contraception cohort) and bottom (of control cohort) along the x-axis. Red and violet lines represent estrogen and progesterone hormones, respectively. The vertical green line represents the onset of the ovulation phase and separates the follicular and luteal phases. Comparison of absolute median values (over 60 s) in all six different measurement points are represented as boxplots for nine selected VOCs. Four potentially endogenous VOCs from all women, control-and contraception cohort during different phases of the menstrual cycle are plotted in Fig. 2 and the same is shown for other five potentially exogenous VOCs in Supplementary Fig. S1 . From all pair-wise multiple comparisons, a colored '*' is assigned on those which are significantly (i.e. P-value ≤ 0.005) different with reference to the corresponding medians from the initial menstrual bleeding phase.
Discussion
We observed pronounced changes in exhaled alveolar VOC concentrations throughout the menstrual cycles. These changes mirrored many investigated metabolic effects induced by monthly endocrine regulations. Eventually, VOC exhalations in the contraception cohort greatly differed compared to the control cohort. Observed changes were VOC specific. Changes in certain endogenous and blood-borne VOCs occurred at the follicular and luteal phases. These changes turned out to be most prominent at the ovulation event in the control cohort. The synthetic hormones, present in oral contraceptive pills do not appear directly in exhaled breath.
Nevertheless, we could demonstrate that natural menstrual effects onto some exhaled VOCs disappeared under the presence of contraception. Our results can facilitate and inspire future investigation in noninvasive metabolic monitoring of numerous biochemical-, physiological-and metabolic processes.
Ammonia exhalation. The major source of breath ammonia is protein metabolism 28 and its exhalation depends on changes of blood-pH e.g. due to respiratory acidosis or alkalosis 20 . In the control cohort, significantly decreased ammonia exhalation just after periods can be attributed to menstruation driven loss of functional endometrial epithelium and consecutive low abundance of plasma progesterone. Progesterone has a catabolic effect on protein metabolism pathways [37] [38] [39] , whereas estrogen mediates the activity of cerebral and endometrial progesterone receptors 40, 41 . Ammonia concentrations returned to initial range during the mid-follicular phase presumably due to an increase in number and sensitivity of progesterone receptors and elevated plasma estrogen. The most pronounced and significant decrease in exhaled ammonia concentrations occurring at the ovulation event in the control group could be assigned to the decreased estrogen and low progesterone levels. Due to the regular oral intake of these hormones by the contraception cohort, ammonia exhalation did not change significantly throughout the duration of the study.
Acetone exhalation. Acetone is mainly produced via glucose and fat metabolism 42 . Acetone exhalation closely mirrored the ammonia profile. An overall significant increase in acetone exhalation during mid-follicular phase can be attributed to higher plasma estrogen. Estrogen and its receptors play a crucial role in cellular energy metabolism 43 . Although acute insulin action on glucose metabolism remained unaffected by estradiol treatment 44 , the risk of type-II diabetes was observed to increase with longstanding estrogen administration 45 . Estrogen stimulates blood glucose transport to cells and its metabolism by up-regulating glycolytic kinase enzymes in the cytoplasm 43 . Moreover, estrogen is accounted for improved surfactant production and alveologenesis and thereby, can increase alveolar elimination of highly water soluble compounds e.g. acetone and ammonia 46, 47 . Exhaled alveolar acetone concentrations decreased significantly at ovulation in the control cohort probably due to a pronounced decline of circulating estrogen. Acetone exhalation did not behaved alike in the contraception cohort due to constant oral supply of estrogen. An overall significant rise in acetone during luteal phase can be assigned to estrogen rise. Consecutively, increased progesterone can antagonize the insulin action in adipose tissue 37 and will increase lipolysis. Isoprene exhalation. Isoprene is supposed to originate predominantly from the mevalonate pathway of cholesterol biosynthesis 48 . Although liver and intestine are the central organ for total cholesterol regulation, all cells express its biosynthetic enzymes to maintain membrane integrity. Significantly elevated isoprene exhalation during ovulation phase in the control cohort can be attributed to supposedly high plasma estrogen. Estrogen and its receptor expressions facilitate mitochondrial β-oxidation of fatty acid and cytoplasmic oxidation of pyruvate, which derive Acetyl Co-A and thereby, trigger the mevalonate pathway 43 . Overall, lipoprotein cholesterol abundance changes in response to varying estrogen levels. Evidence suggests that total cholesterol and low density lipoprotein-C are maximized during the follicular phase and drop during the luteal phase, with high density lipoprotein-C highest around ovulation 49 . Cholesterol is the precursor for the synthesis of steroid hormones 50 . Significantly elevated isoprene concentrations may thus indicate an increased rate of cholesterol biosynthesis that contributes to higher plasma concentrations of both sex hormones required for the subsequent luteal phase. In human cell lines, synthetic progesterone inhibits cholesterol biosynthesis 51 . Thus, the constant intake of synthetic progesterone and estrogen may have led to a decreased isoprene concentration in the middle of the cycle in the contraception cohort. Interestingly, two participants (P-16 and P-21) who have continuously been taking combined-oral contraception for more than 10 years, exhaled no traceable isoprene. This could be due to the progesterone driven suppression of enzymes responsible for the mevalonate pathway.
DMS exhalation. DMS is mainly produced via methylation of methionine by anaerobic gut bacterial colony 52 . Active estrogen maintains the growth and diversity of systemic flora and thereby regulates DMS exhalation. In contrast to the control cohort, a significantly decreased DMS exhalation throughout the cycles under contraception can be assigned to a possible decrease in estrogen activity. While looking for a possible cause we came across published evidences that synthetic progesterone can cause antibacterial effects on the gut flora 53 . Researchers evidenced that antibiotic administrations may often result in contraceptive failure 54, 55 . As there is no certain systemic interaction between antibiotics and oral contraceptives, the explanation of such cases remained unclear. Here, the suppressed DMS exhalations in the contraception cohort indicates a possible antibacterial activity of the daily ingested synthetic progesterone via oral pills. DMS exhalation was different in the 2 nd menstrual bleeding phase in the contraception cohort most possibly due to the fact that the half-life of the synthetic progesterone is longer than the half-life of the natural hormone. Intestinal bacteria play an important role in estrogen metabolism by secreting β-glucuronidase, an enzyme that de-conjugates estrogen into its active form 56 . Antibiotics may cause dysbiosis of gut microbiota 57 , which can result in decreased de-conjugation and therefore, in down-regulation of plasma estrogen. Vice versa, estrogen deficiency suppresses microbial diversity and abundance of intestinal bacteria that are related to immune homeostasis 58 . Thus, our observation supports the fact that co-administration of oral contraceptive and antibiotic drugs should be avoided.
Exhalation of exogenous VOCs. Varying and nonspecific effects were observed on exogenous VOCs.
Breath hydrogen sulphide is sourced from oral bacterial emissions and AMS is known to originate from food constituent e.g. garlic, onions etc 59 . Here, hydrogen sulphide exhalation did not change whereas AMS showed similar tendencies as DMS in both cohorts. This may indicate a parallel origin of breath AMS from gut flora and its regulations via sex hormones. AMS remained different in the 2 nd MB phase due to similar reasons indicated for DMS exhalation. Other exogenous VOCs e.g. benzene and toluene mainly accumulate from environmental exposure 60 . The potential source of furan is smoking. Acetonitrile is related to smoking and environmental exposure. Isopropanol and limonene are used as flavoring agents in food, beverages or mouthwash as well as in disinfectants at clinical environment 59 . Due to variable inspiratory concentrations of these VOCs throughout the study period, no systematic effects of estrogen and progesterone were observed. This emphasizes the fact that determination of inspiratory concentrations is mandatory for rational clinical interpretation of exhaled breath markers.
It is well known that the natural menstrual cycle or contraceptive therapy may predominantly affect carbohydrate, glucose, lipid and protein metabolism by up-or down-regulating those pathways 37, 43 . As endogenous VOCs are known to originate from or are also regulated by those metabolic processes, observed changes in VOC exhalation can be used to monitor systemic/metabolic effects induced by different menstrual phases or via oral contraception. Exogenous substances such as benzene or toluene, acetonitrile or furans may accumulate due to environmental exposition, smoking habits and intake from food or beverages. The four substances selected for monitoring (ammonia, acetone, isoprene and DMS - Table 1 , Fig. 2 ) are known to be mainly endogenous. The fact, that characteristic changes of the selected compounds were observed during the menstrual cycle regardless of different lifestyles and nutrition further supports the hypotheses, that these changes were linked to metabolic changes rather than to lifestyle.
As our prime interest laid on the noninvasive assessment of qualitative effects due to natural menstrual changes and changes under oral contraceptives, quantitative invasive measurements of plasma hormone concentrations were not obligatory in this study. There were not any specific VOCs or volatile hormones that appeared directly in the breath of normal or contraceptive subjects. Rather than looking for specific markers, we developed an in vivo clinical setup to observe the actual potential of volatile profiling to follow-up natural or therapy induced metabolic changes within a biologically comparable study population. Despite vast confounding limitations and challenges in the metabolomics field, we were able to demonstrate consistent and comparable changes in all participants with substantially low variations; even in absolute values. Consequently, most of those changes were reproduced (i.e. statistically indifferent) once the reference phase was repeated in both cohorts. This result was obtained through repeated measurements, which were applied under stable, optimized and constant state-of the-art experimental conditions.
In conclusion, via applying an advanced real-time analytical technique we monitored rapidly occurring physiological and metabolic changes, induced by nature derived menstrual rhythm in young and healthy adult women. Inclusion of a biologically comparable (i.e. age, gender and BMI matched) cohort of oral contraceptive subjects ScIenTIfIc RePoRTS | (2018) 8:10838 | DOI:10.1038/s41598-018-29221-z allowed us to suppress the natural endocrine rhythm and reliably assign the observed changes to hormonal regulations. Observed effects were same and comparable in every participant from the same cohort. These phenomena clearly demonstrate the unique strength of noninvasive metabolic profiling of menstrual cycle homeostasis via exhaled VOC concentrations and its future possible applications for the qualitative assessment of oral contraception or hormonal therapy. These findings could expand our present state of basic and medical knowledge on menstrual endocrinology, metabolomics and clinical breath research. These outcomes are innovative, novel and significantly important to be translated into metabolic follow-up of pregnancy, menopause and post-menopausal complications (e.g. hormonal imbalance, loss of bone mineral density, osteoporosis and cardiomyopathy etc.) in ageing societies by means of noninvasive breath-gas analysis. An intelligible and comprehensive adaptation of our model into certain advanced sensor-based applications may attribute to unconventional avenues towards noninvasive point of care (PoC) monitoring of female health via exhaled breath-gas analysis in the future.
Methods
Our experiments were carried out in accordance with Declaration of Helsinki guidelines. Ethical approval from the Institutional Ethics Committee (IEC, University Medical Centre Rostock, Germany) and signed informed consent from 24 young and healthy women (aged between 18-45 years) were obtained. Among these women, 12 were undertaking combined oral contraceptive pills (i.e. contraception cohort) and other 12 were not using any female contraception (i.e. control cohort).
Only regularly (without early or delayed period problems) menstruating women with no recent pregnancy, miscarriage or expectation were included randomly. Women with a history of any acute or chronic disease and undergoing therapy or dietary supplements were excluded. Conjugal status as well as smoking and/or drinking habits were also recorded upon inclusion. Subject's demographic information along with clinically relevant parameters (e.g. inclusion/exclusion criteria) is listed in Table 2 .
Study Protocol. We started breath sampling for each woman during her menstruation bleeding phase and then repeated follow-ups with defined intervals until the next bleeding. The series of our six measurement points were as follows: All volunteers rested in the sitting position for 10 min before the actual measurement in order to minimize all hemodynamic changes from preceded standing or walking. Each subject maintained a normal sitting position 18 and performed oral breathing (inhalation and exhalation through mouth only) 59 via a sterilized Teflon-mouthpiece of 2.5 cm diameter 61 . After performing one minute of paced breathing (with a fixed normal respiratory rate of 12 breaths/min by following the sound of a metronome) they continued another 2 min of spontaneous breathing (metronome was muted at this time). Mouthpieces were reused after sterilization. In order to avoid any partial/unsupervised nasal breathing, we used nose clips in this setup.
PTR-ToF-MS measurements. Breath VOCs were measured continuously in real-time via a high-resolution proton transfer reaction-time of flight-mass spectrometry [PTR-ToF-MS 8000] (Ionicon Analytik GmbH, Innsbruck, Austria). The functional principle and optimized conditions of our instrument for online breath sampling and analysis were described in previous studies 26, 31 . Briefly the following steps take place: VOC data recording and mass calibration: After every minute a new data file was recorded automatically and the mass scale was recalibrated after each run (60 s). We used the following masses for mass calibration: 21 VOC data processing. VOCs were measured in counts per seconds (cps) and corresponding intensities were normalized onto primary ion (H 3 O + ) counts. As PTR measures the VOCs continuously, inspiratory/ambient and expiratory data are recorded seamlessly. Thus, we applied a custom-made data processing algorithm ('Breath tracker'; based on MATLAB version 7.12.0.635, R2011a) to identify expiratory and inspiratory phases 31, 35 . Here, we used acetone as the tracker mass due to its endogenous origin and relatively higher abundance in exhalation than in inspiratory air.
VOCs were tentatively identified via their sum formulas and protonated masses are listed in Table 1 and  Table S1 . The high mass resolution of the PTR-ToF-MS-8000 enables very accurate assignment of a chemical formula to its measured mass. Thus, within the discussion VOCs are referred to by their name or sum formula.
Reduction of intra-individual variations for the heat-map. All in vivo studies are bound to have intra-individual variations. In this longitudinal approach, each volunteer was considered as her own control. Thus, during the presentation of relative changes throughout the menstrual cycle in the heat-map (Fig. 1) , intra-individual variations were reduced by normalizing VOC concentrations onto the corresponding values in the third breath (from the second minute) of the first menstruation phase.
Statistical analysis. Due to the non-parametric distribution of data, median values were considered for all statistical analysis. For statistical comparisons between the 6 different measurement points (i.e. each group) we treated the data as follows:
At first, the median (from all 24 participants) of exhaled VOC concentrations (absolute values) in each group were calculated (i.e. over the 60 s of measurement from the spontaneous breathing phase). Secondly, the same as above were calculated separately for the contraception-and control cohort (12 subjects in each cohort).
Statistically significant differences in all above-mentioned parameters were evaluated via repeated measurement ANOVA on ranks (Friedman repeated measures analysis of variance on ranks, Shapiro-Wilk test for normal distribution and post hoc Student-Newman-Keuls method for pairwise multiple comparisons between all groups; P-value ≤ 0.005) in SigmaPlot (version 13) software. From all pairwise comparisons, we selected those referring to the corresponding values from the first menstrual bleeding phase [MB (D_0-4) ].
Data availability. Authors comply with the data availability policy of Scientific Reports.
